{"name":"Servier Affaires Médicales","slug":"servier-affaires-m-dicales","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Diabeton 60 MR","genericName":"Diabeton 60 MR","slug":"diabeton-60-mr","indication":"Type 2 diabetes mellitus","status":"phase_2"}]}],"pipeline":[{"name":"Diabeton 60 MR","genericName":"Diabeton 60 MR","slug":"diabeton-60-mr","phase":"phase_2","mechanism":"Diabeton 60 MR is a sustained-release formulation that provides prolonged glucose-lowering effects by inhibiting glucagon-like peptide-1 (GLP-1) degradation.","indications":["Type 2 diabetes mellitus"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTFByZGhHdnRKdWp0OWl2MjNZOHhtVF85XzRJOFpoRUpnYnBXRDhKRk5qREZCam1QeEJmLXNjUzd6SmpXNl9pd294NHVVMFhjR2RfU2dvTVJVbU9DVjJhOGFMc3ByNnBoSm84S2RSX3BJOGtjNWlxMTRTU2Zn?oc=5","date":"2025-12-20","type":"trial","source":"acsjournals.onlinelibrary.wiley.com","summary":"Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trials - acsjournals.onlinelibrary.wiley.com","headline":"Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer tri","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTFBEaUlUdXR0c1RFTXc1T1pjSTVVNThocGdUYUtyRkdaMjVGMTRrcG56bnQwYVVpUzBGSHBFdXFKZ3hfMU1SVFR6TllvZWhNdEhEVXhNTExMcWgzSnB1aEJsRGVrNjd6dw?oc=5","date":"2025-08-30","type":"pipeline","source":"MedPage Today","summary":"Novel Antihypertensive Effective for Uncontrolled, Resistant Hypertension - MedPage Today","headline":"Novel Antihypertensive Effective for Uncontrolled, Resistant Hypertension","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE1heEJUdkc4d0NTV29aenRfUFJFZmVUZVJ2RFZkVm5FX0d2dTYxdC0tNHMzem5jNXItd0FJQk9lU0IwWmxQbWwtVDEzLXA2c1AwNVRlZkcyeXZIZlVnVUdQNW55RVdzQQ?oc=5","date":"2024-09-03","type":"pipeline","source":"MedPage Today","summary":"Novel Drug Reduced Triglycerides, Risk of Pancreatitis in Persistent Chylomicronemia - MedPage Today","headline":"Novel Drug Reduced Triglycerides, Risk of Pancreatitis in Persistent Chylomicronemia","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}